How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Substance Abuse Screening Market
- By Screening Method: Urine Drug Testing, Saliva Drug Testing, Hair Follicle Testing, Blood Drug Testing, Sweat Patch Testing
- By Substance Type: Alcohol, Opioids, Cannabinoids, Amphetamines, Cocaine, Benzodiazepines
- By End User: Hospitals, Rehabilitation Centers, Workplace Testing, Diagnostic Laboratories, Correctional Facilities
- By Technology: Immunoassay, Chromatography, Mass Spectrometry, Enzyme-Linked Immunosorbent Assay (ELISA)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Urine Drug Testing leads By Screening Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.169 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.177 →
Full report · locked preview
Everything inside the Substance Abuse Screening Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Screening Method 5
Substance Type 6
End User 5
Technology 4
Companies profiled
Abbott Laboratories
Thermo Fisher Scientific
Quest Diagnostics
LabCorp
Siemens Healthineers
Bio-Rad Laboratories
Alere Inc. (now part of Abbott)
OraSure Technologies
Psychemedics Corporation
PharmChem Laboratories
NMS Labs
Redwood Toxicology Laboratory
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Quest Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →LabCorp
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Alere Inc. (now part of Abbott)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →OraSure Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Psychemedics Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →PharmChem Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →NMS Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Redwood Toxicology Laboratory
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →MedTox Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sino Biopharmaceutical Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Alkermes
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$12,012M by 2033 · 10.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Urine Drug Testing49.6
- Saliva Drug Testing10.8
- Hair Follicle Testing10.1
- Blood Drug Testing15.1
- Sweat Patch Testing14.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,768M → $3,880M · 10.3%
Europe$1,232M → $3,052M · 12.0%
Asia Pacific$1,125M → $2,663M · 11.4%
Latin America$696.3M → $1,595M · 10.9%
Middle East and Africa$535.6M → $1,347M · 12.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.582026
10.582027
10.612028
10.612029
10.622030
10.632031
10.652032
10.652033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories21.6
- Thermo Fisher Scientific24.2
- Quest Diagnostics5.3
- LabCorp6.5
- Siemens Healthineers7.5
- Bio-Rad Laboratories6.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Screening Method40.1%
Substance Type22.9%
End User20.5%
Technology16.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.9
- Europe24.3
- Asia Pacific21.2
- Latin America12.7
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 95 | 97 | 76 | 76 | 86 | 92 | 87 |
| Thermo Fisher Scientific | 90 | 74 | 74 | 88 | 85 | 93 | 84 |
| Quest Diagnostics | 79 | 62 | 64 | 73 | 70 | 75 | 71 |
| LabCorp | 60 | 70 | 70 | 80 | 81 | 61 | 70 |
| Siemens Healthineers | 66 | 63 | 73 | 57 | 61 | 63 | 64 |
| Bio-Rad Laboratories | 56 | 58 | 66 | 68 | 47 | 49 | 57 |
| Alere Inc. (now part of Abbott) | 49 | 59 | 61 | 49 | 53 | 54 | 54 |
| OraSure Technologies | 57 | 41 | 45 | 50 | 52 | 36 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Thermo Fisher Scientific
- Quest Diagnostics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Thermo Fisher Scientific | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Quest Diagnostics | ✓ | ✓ | − | ◐ | ◐ | ✓ |
| LabCorp | − | ◐ | ◐ | ◐ | ✓ | − |
| Siemens Healthineers | ◐ | ◐ | − | − | − | − |
| Bio-Rad Laboratories | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Alere Inc. (now part of Abbott) | − | − | ◐ | ◐ | ◐ | − |
| OraSure Technologies | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories87
2Thermo Fisher Scientific84
3Quest Diagnostics71
4LabCorp70
5Siemens Healthineers64
6Bio-Rad Laboratories57
7Alere Inc. (now part of Abbott)54
8OraSure Technologies47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesThermo Fisher Scientific
Challenger2
Strong scale, closing on the leaders.
Quest DiagnosticsLabCorp
Contender2
Focused players with pockets of strength.
Siemens HealthineersBio-Rad Laboratories
Niche2
Specialists in a single segment or region.
Alere Inc. (now part of Abbott)OraSure Technologies
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Screening Method in North America, then scale across Substance Abuse Screening Market — a $152M beachhead inside a $2.34B market.
Beachhead (SOM)$152Mobtainable near-term
Serviceable (SAM)$804Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Urine Drug Testing
Best fit — highest urgency & budget in Screening Method.
Economic buyer77 fit
Saliva Drug Testing
Strong fit — clear ROI and a fast path to value.
End user66 fit
Hair Follicle Testing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Screening Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Substance Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel27%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Screening Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Substance Abuse Screening Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified22%
Evaluation11%
Closed-won6%
$15.9KCAC
$88KLTV
5.5:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Substance Abuse Screening Market is a resilient opportunity — $1.26B by 2033, compounding at 4.4%.
TAM · 2025$892Mtoday
TAM · 2033$1.26Bforecast
CAGR4.4%2027–2033
Cumulative$9.59Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.26BTotal addressable market
SAM$463MServiceable available market
SOM$76MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Screening Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Screening Method moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.26BLarge & growingTAM by 2033 at 4.4% CAGR
$463MServiceable nowreachable with today’s model
$76MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$981MBear2.9% CAGR
$1.26BBase4.4% CAGR
$1.61BBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Substance Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Substance Abuse Screening Market — a $6.68B market by 2033. Plan: grow share from 10.8% to 18.7%.
Market size · 2033$6.68Btotal addressable
Market CAGR6.9%2027–2033
Target share18.7%from 10.8% today
Revenue ambition$1.25Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.8% | 18.7% | On track |
| Revenue | $682M | $1.25B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 28.3% | 44.1% | Ahead |
| Customer retention | 84.6% | 94.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Screening Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Substance Type capability
A defensible second engine — invest in Substance Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Screening Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Substance Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $145M capacity & capability investment
- Greenlight bolt-on M&A in Substance Type
- Authorise North America expansion plan
- Fund R&D program for Screening Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Substance Abuse Screening Market conversation — a $2.24B market you can size, segment and defend in minutes.
Market size · 2033$2.24Btotal opportunity
Growth4.3%CAGR to 2033
Addressable buyers1,403+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Screening Method
Goal Grow share in Screening Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 2 mopayback period
$40K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Abbott LaboratoriesThermo Fisher ScientificQuest DiagnosticsLabCorpSiemens HealthineersBio-Rad LaboratoriesAlere Inc. (now part of Abbott)OraSure Technologies+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Substance Abuse Screening Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Substance Abuse Screening Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Substance Abuse and Addiction Treatment Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportSubperiosteal Dental Implants Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportSuboxone and Methadone Treatment Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportSubmucosal Tissue Lifting Agent Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportSubmucosal Lifting Injection Solution Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportSubmucosal Lifting Agent Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportSubmucosal Injection Solution Market
Market size, share, segmentation and regional forecast.
$806M market · 2025 base year
View reportSubmucosal Injections Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportSubmucosal Injection Agent Market
Market size, share, segmentation and regional forecast.
$386M market · 2025 base year
View reportSubmucosal Injectable Composition Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportSub-Micrometer Computed Tomography Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportSubjective Refraction Units Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.